Jan 17 (Reuters) - NeuBase Therapeutics Inc :
* NEUBASE THERAPEUTICS INC: ON JAN 12, BOARD TERMINATED EMPLOYMENT OF DIETRICH A. STEPHAN, PH.D. AS CHIEF EXECUTIVE OFFICER OF COMPANY, WITHOUT CAUSE
* NEUBASE THERAPEUTICS- APPOINTED TODD P. BRANNING, WHO HAS SERVED AS COMPANY'S CFO SINCE JANUARY 2022, AS INTERIM CEO
* NEUBASE THERAPEUTICS INC: DIETRICH A. STEPHAN IS EXPECTED TO CONTINUE TO SERVE ON BOARD
Further company coverage:
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments